Samir Agrawal

Dr. Samir Agrawal is a Senior Lecturer and Honorary Consultant in Haemato-Oncology at the Blizard Institute, Queen Mary University of London. He holds a BSc, MBChB, PhD, and fellowships from the Royal College of Physicians (FRCP) and Royal College of Pathologists (FRCPath).

Research Focus: His work spans blood cancer diagnostics, antimicrobial stewardship (AMS), and invasive fungal disease (IFD) management in high-risk haematology patients. Key contributions include:

• Developing the CD160-ROR1 assay for minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL), with pending patents
• Co-authoring ECIL-6 guidelines for antifungal treatment in leukemia and transplant patients
• Creating the Fungal Audit Tool for Stewardship (FATs) to improve AMS

Publication Trends: Agrawal’s research bridges haematology, oncology, and infectious diseases, emphasizing:

• CD160’s role in B-cell malignancies (2010–2020)
• Standardization of IFD diagnostics via clinical guidelines (2016)
• Integration of flow cytometry and biomarker discovery for cancer therapy (2011, 2020)
• T-cell dysfunction in lymphoid malignancies (1998)

Supervision & Collaboration: He mentors clinical fellows in implementing the FATs audit tool and collaborates with UK centres on haemato-oncology and IFD research. Agrawal also leads educational initiatives like the UK’s largest Fungal Update conference.